Oramed Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Oramed Pharmaceuticals
ORMP Stock  USD 2.95  0.20  6.35%   
Analyzing historical trends in various income statement and balance sheet accounts from Oramed Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Oramed Pharmaceuticals' valuation are summarized below:
Gross Profit
13 K
Profit Margin
21.926
Market Capitalization
117.6 M
Enterprise Value Revenue
3.0214
Revenue
2 M
There are currently one hundred twenty trending fundamental ratios for Oramed Pharmaceuticals that can be evaluated and compared over time across competitors. Investors and active traders are advised to check out Oramed Pharmaceuticals' recent fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 12/28/2025, Enterprise Value is likely to grow to about 80.5 M, while Market Cap is likely to drop slightly above 88.6 M.

Oramed Pharmaceuticals Total Revenue

0.0

Check Oramed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oramed Pharmaceuticals' main balance sheet or income statement drivers, such as Selling General Administrative of 3.5 M, Other Operating Expenses of 10.8 M or Research Development of 7.6 M, as well as many indicators such as Price To Sales Ratio of 74.82, Dividend Yield of 0.0 or PTB Ratio of 0.71. Oramed financial statements analysis is a perfect complement when working with Oramed Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Oramed Stock
Check out the analysis of Oramed Pharmaceuticals Correlation against competitors.
To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.

Oramed Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities5.4 M5.7 M6.5 M
Slightly volatile
Common Stock Shares Outstanding42.9 M40.8 M20 M
Slightly volatile
Other Stockholder Equity338.5 M322.4 M136 M
Slightly volatile
Total Liabilities9.3 M9.9 M11.5 M
Slightly volatile
Common Stock504 K480 K243.9 K
Slightly volatile
Total Assets163 M155.3 M68.9 M
Slightly volatile
Accounts Payable824.5 K789 K900.8 K
Slightly volatile
Liabilities And Stockholders Equity163 M155.3 M68.9 M
Slightly volatile
Non Current Liabilities Total4.3 M4.2 M5 M
Slightly volatile
Other Current Assets1.4 M1.3 M686 K
Slightly volatile
Total Current Assets150.4 M143.2 M57.6 M
Slightly volatile
Short and Long Term Debt Total353.4 K372 K3.4 M
Slightly volatile
Property Plant And Equipment Net1.2 M1.1 M430.7 K
Slightly volatile
Non Current Assets Total10.3 M12.1 M11.2 M
Slightly volatile
Non Currrent Assets Other37.1 K39.1 K1.6 M
Pretty Stable
Short Term Debt205.2 K216 K3.3 M
Slightly volatile
Short Term Investments91.9 M87.5 M39.1 M
Slightly volatile
Net Receivables218 K367.2 K363.8 K
Very volatile
Inventory13.7 K14.4 K16.1 K
Slightly volatile
Current Deferred Revenue2.3 M1.5 M1.5 M
Slightly volatile
Capital Lease Obligations546.3 K372 K236.2 K
Slightly volatile
Net Invested Capital145.5 M146.3 M71 M
Slightly volatile
Long Term Investments17.4 M10.9 M8.5 M
Slightly volatile
Property Plant And Equipment Gross1.2 M1.1 M536.2 K
Slightly volatile
Capital Stock472.8 K480 K341.4 K
Slightly volatile
Non Current Liabilities Other83 K60 K169.5 K
Slightly volatile
Net Working Capital115 M137.5 M62.4 M
Slightly volatile
Short and Long Term Debt40.8 M45.9 M50.1 M
Slightly volatile

Oramed Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative3.5 M6.5 M4.1 M
Slightly volatile
Other Operating Expenses10.8 M12.8 M12.8 M
Slightly volatile
Research Development7.6 M6.3 M8.6 M
Slightly volatile
Total Operating Expenses10.8 M12.8 M12.8 M
Slightly volatile
Interest Expense696.1 K853 K551.4 K
Slightly volatile
Cost Of Revenue151.5 K173.7 K299.2 K
Slightly volatile
Net Interest Income2.9 M4.1 M1.4 M
Slightly volatile
Interest Income3.9 M5 M1.8 M
Slightly volatile
Reconciled Depreciation116.8 K193 K44.9 K
Slightly volatile
Selling And Marketing Expenses245.4 K258.3 K1.6 M
Slightly volatile

Oramed Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.6 M9.1 M11.7 M
Slightly volatile
End Period Cash Flow57.1 M54.4 M18 M
Slightly volatile
Depreciation202.7 K193 K57.7 K
Slightly volatile
Stock Based Compensation2.3 M4.1 M2.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio74.8262.55105
Pretty Stable
Days Sales Outstanding191201232
Slightly volatile
Average Payables645.2 K614.5 K580.4 K
Slightly volatile
Stock Based Compensation To Revenue2.972.831.7856
Slightly volatile
Capex To Depreciation0.08860.09332.841
Slightly volatile
EV To Sales69.9491.14100
Very volatile
Payables Turnover0.220.280.2615
Slightly volatile
Sales General And Administrative To Revenue3.977.233.9954
Very volatile
Average Inventory12.4 K15.4 K16.3 K
Very volatile
Research And Ddevelopement To Revenue7.667.78.2018
Pretty Stable
Capex To Revenue0.180.170.0728
Slightly volatile
Days Payables Outstanding2.2 K1.3 K1.8 K
Pretty Stable
Current Ratio26.4525.192813.6158
Slightly volatile
Receivables Turnover0.981.881.8999
Very volatile
Debt To Equity0.00240.00250.0558
Pretty Stable
Capex Per Share4.0E-44.0E-40.0035
Slightly volatile
Average Receivables82.5 K86.8 K103.6 K
Slightly volatile
Revenue Per Share0.02840.02990.077
Very volatile
Debt To Assets0.00230.00240.0257
Very volatile
Graham Number2.833.193.4735
Slightly volatile
Operating Cycle191201232
Slightly volatile
Days Of Payables Outstanding2.2 K1.3 K1.8 K
Pretty Stable
Total Debt To Capitalization0.00240.00250.0394
Pretty Stable
Debt Equity Ratio0.00240.00250.0558
Pretty Stable
Quick Ratio26.4525.192813.611
Slightly volatile
Days Of Sales Outstanding191201232
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00211.0129
Slightly volatile
Fixed Asset Turnover0.930.9839.2257
Slightly volatile
Debt Ratio0.00230.00240.0257
Very volatile
Price Sales Ratio74.8262.55105
Pretty Stable
Asset Turnover0.00660.0070.0293
Slightly volatile
Gross Profit Margin0.650.870.6639
Slightly volatile

Oramed Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap88.6 M98.8 M153.1 M
Slightly volatile
Enterprise Value80.5 M44.8 M139.1 M
Slightly volatile

Oramed Fundamental Market Drivers

Oramed Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oramed Pharmaceuticals Financial Statements

Oramed Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Oramed Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Oramed Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oramed Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 M2.3 M
Cost Of Revenue173.7 K151.5 K
Stock Based Compensation To Revenue 2.83  2.97 
Sales General And Administrative To Revenue 7.23  3.97 
Research And Ddevelopement To Revenue 7.70  7.66 
Capex To Revenue 0.17  0.18 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(13.53)(14.21)

Pair Trading with Oramed Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Oramed Stock

  0.81HCM HUTCHMED ChinaPairCorr
  0.78002332 Zhejiang Xianju PharPairCorr
  0.74KG Kestrel Group, Symbol ChangePairCorr
  0.69603676 Tibet Weixinkang MedicinePairCorr
  0.69600381 Qinghai Spring MedicinalPairCorr
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Oramed Stock Analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY